176 related articles for article (PubMed ID: 24395671)
1. A novel splice site mutation in the noncoding region of BRCA2: implications for Fanconi anemia and familial breast cancer diagnostics.
Bakker JL; Thirthagiri E; van Mil SE; Adank MA; Ikeda H; Verheul HM; Meijers-Heijboer H; de Winter JP; Sharan SK; Waisfisz Q
Hum Mutat; 2014 Apr; 35(4):442-6. PubMed ID: 24395671
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.
García MJ; Fernández V; Osorio A; Barroso A; Fernández F; Urioste M; Benítez J
Carcinogenesis; 2009 Nov; 30(11):1898-902. PubMed ID: 19737859
[TBL] [Abstract][Full Text] [Related]
3. Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
Chen X; Truong TT; Weaver J; Bove BA; Cattie K; Armstrong BA; Daly MB; Godwin AK
Hum Mutat; 2006 May; 27(5):427-35. PubMed ID: 16619214
[TBL] [Abstract][Full Text] [Related]
4. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members.
Thomassen M; Blanco A; Montagna M; Hansen TV; Pedersen IS; Gutiérrez-Enríquez S; Menéndez M; Fachal L; Santamariña M; Steffensen AY; Jønson L; Agata S; Whiley P; Tognazzo S; Tornero E; Jensen UB; Balmaña J; Kruse TA; Goldgar DE; Lázaro C; Diez O; Spurdle AB; Vega A
Breast Cancer Res Treat; 2012 Apr; 132(3):1009-23. PubMed ID: 21769658
[TBL] [Abstract][Full Text] [Related]
5. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
Machackova E; Foretova L; Lukesova M; Vasickova P; Navratilova M; Coene I; Pavlu H; Kosinova V; Kuklova J; Claes K
BMC Cancer; 2008 May; 8():140. PubMed ID: 18489799
[TBL] [Abstract][Full Text] [Related]
6. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
Dos Santos ES; Caputo SM; Castera L; Gendrot M; Briaux A; Breault M; Krieger S; Rogan PK; Mucaki EJ; Burke LJ; ; Bièche I; Houdayer C; Vaur D; Stoppa-Lyonnet D; Brown MA; Lallemand F; Rouleau E
Breast Cancer Res Treat; 2018 Apr; 168(2):311-325. PubMed ID: 29236234
[TBL] [Abstract][Full Text] [Related]
8. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
[TBL] [Abstract][Full Text] [Related]
9. Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 gene.
Degrolard-Courcet E; Sokolowska J; Padeano MM; Guiu S; Bronner M; Chery C; Coron F; Lepage C; Chapusot C; Loustalot C; Jouve JL; Hatem C; Ferrant E; Martin L; Coutant C; Baurand A; Couillault G; Delignette A; El Chehadeh S; Lizard S; Arnould L; Fumoleau P; Callier P; Mugneret F; Philippe C; Frebourg T; Jonveaux P; Faivre L
Eur J Hum Genet; 2014 Aug; 22(8):979-87. PubMed ID: 24301060
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the novel fanconi anemia gene SLX4/FANCP in familial breast cancer cases.
Bakker JL; van Mil SE; Crossan G; Sabbaghian N; De Leeneer K; Poppe B; Adank M; Gille H; Verheul H; Meijers-Heijboer H; de Winter JP; Claes K; Tischkowitz M; Waisfisz Q
Hum Mutat; 2013 Jan; 34(1):70-3. PubMed ID: 22911665
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
[TBL] [Abstract][Full Text] [Related]
13. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.
Casadei S; Norquist BM; Walsh T; Stray S; Mandell JB; Lee MK; Stamatoyannopoulos JA; King MC
Cancer Res; 2011 Mar; 71(6):2222-9. PubMed ID: 21285249
[TBL] [Abstract][Full Text] [Related]
14. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.
Sawyer SL; Tian L; Kähkönen M; Schwartzentruber J; Kircher M; ; ; Majewski J; Dyment DA; Innes AM; Boycott KM; Moreau LA; Moilanen JS; Greenberg RA
Cancer Discov; 2015 Feb; 5(2):135-42. PubMed ID: 25472942
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.
Seal S; Barfoot R; Jayatilake H; Smith P; Renwick A; Bascombe L; McGuffog L; Evans DG; Eccles D; Easton DF; Stratton MR; Rahman N;
Cancer Res; 2003 Dec; 63(24):8596-9. PubMed ID: 14695169
[TBL] [Abstract][Full Text] [Related]
16. Genotype-cancer association in patients with Fanconi anemia due to pathogenic variants in FANCD1 (BRCA2) or FANCN (PALB2).
McReynolds LJ; Biswas K; Giri N; Sharan SK; Alter BP
Cancer Genet; 2021 Nov; 258-259():101-109. PubMed ID: 34687993
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 whole cDNA analysis in unsolved hereditary breast/ovarian cancer patients.
Montalban G; Bonache S; Bach V; Gisbert-Beamud A; Tenés A; Moles-Fernández A; López-Fernández A; Carrasco E; Balmaña J; Diez O; Gutiérrez-Enríquez S
Cancer Genet; 2021 Nov; 258-259():10-17. PubMed ID: 34237702
[TBL] [Abstract][Full Text] [Related]
18. Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.
Keupp K; Hampp S; Hübbel A; Maringa M; Kostezka S; Rhiem K; Waha A; Wappenschmidt B; Pujol R; Surrallés J; Schmutzler RK; Wiesmüller L; Hahnen E
Mol Genet Genomic Med; 2019 Sep; 7(9):e863. PubMed ID: 31347298
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
